Products
Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Vitamin B12 test kit

Baricitinib

Cat. No.: 0225LY-1291
Purity: ≥99%
Identity: Confirmed by NMR, HPLC, and LC-MS.
Size:
Baricitinib
Add to basket

Product Overview

Description: Baricitinib is an orally active JAK1 and JAK2 inhibitor (IC50: 5.9/5.7 nM) with significant anti-inflammatory, anti-tumor, and immunomodulatory potential.
Synonym: INCB028050; LY3009104; 1187594-09-7; Olumiant; INCB 028050; INCB-028050; 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile; 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile; 2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
CAS No.: 1187594-09-7
Compound CID: 44205240
Formula: C16H17N7O2S
Formula Weight: 371.42

Specification

Targets&IC50: JAK3: >400 nM; TYK2: 53 nM; JAK1: 5.9 nM; JAK2: 5.7 nM
Relative Density: 1.56 g/cm3
Stability: 3 years in powder form.
Storage: Storage at -20°C.
Applications: Baricitinib can be used in immunology research to investigate the selective inhibition of JAK1 and JAK2 signaling.

Library Information

Target: JAK; Chk; Tyrosine kinases
Receptor: Chk2; JAK1; JAK2; JAK3; Tyk2
Pathways: Tyrosine kinase/adaptors; Angiogenesis; JAK/STAT signaling; Cell cycle/Checkpoint; Chromatin/Epigenetic; Stem cell regulation
Plate Number: AOCL-17
Plate Location: e8
Empty Location: a1-h1; a12-h12
Container: 96-well plate
Formulation: 10mM DMSO
DMSO Max Solubility: 250 mg/mL; 673.09 mM
Water Max Solubility: <1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility: <1 mg/mL (insoluble or slightly soluble)
ALogP: 0.36
HBA_Count: 5
HBD_Count: 1
Rotatable Bond: 5
Inquiry
0
Inquiry Basket

Copyright © Protheragen. All rights reserves.